Patents by Inventor Hongqin HU

Hongqin HU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION COMPRISING PD-L1 ANTIGEN-BINDING FRAGMENT AND USE THEREOF
    Publication number: 20240382411
    Abstract: The present application relates to a composition comprising an antigen-binding fragment and an excipient. The antigen-binding fragment comprises an immunoglobulin single variable domain capable of specifically binding to PD-L1 and comprising CDR1-3, the CDR3 comprising an amino acid sequence set forth in SEQ ID NO: 47, and the excipient may comprise proline. The composition has good stability and suitable viscosity and can be used for subcutaneous injection.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 21, 2024
    Inventors: Ting Xu, Kangping Guo, Lihong Yun, Yuanli Wu, Yan Huang, Hongqin Hu
  • PD-L1 binding polypeptide or composite
    Patent number: 11377497
    Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: July 5, 2022
    Assignee: SUZHOU ALPHAMAB CO., LTD.
    Inventors: Ting Xu, Aiwu Zhou, Yuhao Jin, Ling Wang, Jie Wu, Hongqin Hu, Xiaoxiao Wang
  • PD-L1 BINDING POLYPEPTIDE OR COMPOSITE
    Publication number: 20190352404
    Abstract: The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KNO35 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.
    Type: Application
    Filed: January 23, 2018
    Publication date: November 21, 2019
    Applicant: SUZHOU ALPHAMAB CO., LTD.
    Inventors: Ting XU, Aiwu ZHOU, Yuhao JIN, Ling WANG, Jie WU, Hongqin HU, Xiaoxiao WANG